CoChat

Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis

The DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.

Abstract

Background: Preclinical data suggest that metformin may reduce breast cancer incidence and improve cancer prognosis. However, the current evidence in observational studies is inconclusive. A systematic review and meta-analysis was conducted to assess the effect of metformin on the incidence of breast cancer and all-cause mortality in patients with type II diabetes (T2D). Methods: A literature search was performed on Medline, EMBASE, and the Cochrane library from inception to November 2016. Outcomes were incidence of breast cancer and all-cause mortality. Risk of bias and overall certainty of evidence was assessed using the Newcastle-Ottawa Scale and Grading of Recommendations Assessment, Development, and Evaluation (GRADE), respectively. Meta-analyses were performed using the most fully adjusted ORs or HRs and 95% confidence intervals (95% CI) as effect measures. Results: A total of 12 observational studies were included for breast cancer incidence and 11 studies for all-cause mortality. No significant association was found between metformin exposure and incidence of breast cancer (OR = 0.93; 95% CI, 0.85–1.03; I2 = 35%). A 45% risk reduction was observed for all-cause mortality (HR = 0.55; 95% CI, 0.44–0.70; I2 = 81%). Presence of publication bias is strongly suspected for both outcomes using Egger's funnel plots. Conclusions: The use of metformin may improve overall survival in patients with T2D and breast cancer. No effect of metformin on the incidence of breast cancer was observed. Interpretation of results is limited by the observational nature of the studies and resulting biases. Impact: Clinical trials are warranted to determine the role of metformin in breast cancer risk reduction and prognosis. Cancer Epidemiol Biomarkers Prev; 27(6); 627–35. ©2018 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1055-9965.epi-17-0936

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 79 references

Research works printed but not linked: 2

  1. Higgins, 2011, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0
  2. Altman, 1991, Inter-rater agreement, Pract Stat Med Res, 5, 403

Cited by

See all 119

Metadata

Authors
Tang, G. H., Satkunam, M., Pond, G. R., Steinberg, G. R., Blandino, G., Schünemann, H. J., & Muti, P.
Affiliations
  • McMaster University (CA)
  • Instituto Nazionale Tumori Regina Elena (IT)
Corresponding author
Muti, Paola
Venue
Cancer Epidemiology, Biomarkers & Prevention
Published
2018-05-31
Volume
27
Issue
6
Pages
627-635
ISSN
  • 1055-9965 (ISSN-L)
  • 1538-7755
OpenAlex
W2795771650
Cited by
117
References
80
Citations by year
2026: 5 · 2025: 8 · 2024: 13 · 2023: 12 · 2022: 17 · 2021: 18 · 2020: 19 · 2019: 19 · 2018: 6
FWCI
1.52
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Epidemiology Biomarkers & Prevention (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Oncology › Cancer Risks and Factors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
metformin, breast cancer incidence, breast cancer mortality, type 2 diabetes, all-cause mortality, cancer risk reduction, cancer prognosis, publication bias
MeSH terms
Breast Neoplasms, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Metformin, Prognosis, Incidence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.1158/1055-9965.epi-17-0936
The paper
Tang, G. H., Satkunam, M., Pond, G. R., Steinberg, G. R., Blandino, G., Schünemann, H. J., & Muti, P. (2018). Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-17-0936

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.